Novo Nordisk's leadership strategy tested as shareholders signal frustration ahead of vote on board revamp
1. Novo Nordisk announces significant leadership changes amid shareholder discontent. 2. Shares dropped 12% since board shakeup; stock down 58% this year. 3. Increasing competition from Eli Lilly raises concerns about future market position. 4. U.S. market accounts for 56% of Novo's sales, highlighting critical dependence. 5. New board faces skepticism regarding commercial expertise and market strategy.